Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for BioNexus Gene Lab (BGLC) over the last 3 years, with Q3 2025 value amounting to $1.8 million.

  • BioNexus Gene Lab's Shares Outstanding (Diluted Average) fell 0.94% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 0.94%. This contributed to the annual value of $17.8 million for FY2024, which is 1223.92% up from last year.
  • Per BioNexus Gene Lab's latest filing, its Shares Outstanding (Diluted Average) stood at $1.8 million for Q3 2025, which was down 0.94% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Shares Outstanding (Diluted Average) ranged from a high of $18.0 million in Q1 2025 and a low of $1.8 million during Q2 2024
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $8.8 million (2023), whereas its average is $9.6 million.
  • In the last 5 years, BioNexus Gene Lab's Shares Outstanding (Diluted Average) surged by 1223.92% in 2024 and then decreased by 0.94% in 2025.
  • Over the past 3 years, BioNexus Gene Lab's Shares Outstanding (Diluted Average) (Quarter) stood at $15.9 million in 2023, then increased by 12.24% to $17.8 million in 2024, then tumbled by 89.92% to $1.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $1.8 million in Q3 2025, compared to $1.8 million in Q2 2025 and $18.0 million in Q1 2025.